Immunokinases, a novel class of immunotherapeutics for targeted cancer therapy

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Tumor cells possess unique characteristics, such as specific cell surface molecules (e.g., CD30) and genetic alterations (e.g., DAPK2 inactivation), enabling targeted therapeutic strategies.
• Hodgkin lymphoma cells often exhibit CD30 expression and DAPK2 gene inactivation, which inhibits apoptosis, presenting a vulnerability for targeted intervention.

Purpose of the Study:

• To develop a novel tumor-targeting fusion protein for enhanced specificity and reduced systemic toxicity in cancer therapy.
• To investigate the therapeutic potential of restoring a defective tumor suppressor kinase (DAPK2) within tumor cells via a targeted approach.

Main Methods:

• Engineered a fusion protein (DAPK2'-CD30L) combining a CD30-specific ligand with a constitutively active DAPK2 kinase.
• Evaluated the fusion protein's ability to induce apoptosis in CD30-positive, DAPK2-deficient tumor cells in vitro.
• Assessed the in vivo efficacy of the immunokinase fusion protein in a disseminated Hodgkin lymphoma xenograft mouse model.

Main Results:

• The DAPK2'-CD30L fusion protein demonstrated specific induction of apoptosis in CD30(+)/DAPK2(-) tumor cells in vitro.
• Significant prolongation of overall survival was observed in SCID mice bearing disseminated Hodgkin lymphoma xenografts treated with the fusion protein.
• The study validated the targeted delivery of a functional tumor suppressor kinase to cancer cells.

Conclusions:

• Recombinant immunokinases represent a feasible platform for targeted cancer therapy by restoring defective tumor suppressor functions.
• Targeting specific molecular deficits within tumor cells, such as DAPK2 inactivation, offers a promising strategy for selective cancer treatment.
• This approach highlights the potential for developing immunokinase-based therapies with improved tumor specificity and reduced side effects.